BrainSeq: Neurogenomics Data for Psychiatric Disorder Target Discovery

BrainSeq consortium data characterizes genetic and epigenetic regulation of transcription in distinct brain regions across the human lifespan. The project focuses on schizophrenia and mood disorders, using archival brain genomic samples from controls and patients. Seven pharmaceutical companies and a not-for-profit medical research institution generated this data as a precompetitive public resource.

Use Cases

• Identify genetic associations with psychiatric disorders based on brain region transcription data.
• Analyze epigenetic regulation patterns across the human lifespan mentioned in the description.
• Discover novel therapeutic targets for schizophrenia and mood disorders using consortium genomic data.
• Compare transcriptional profiles between distinct brain regions in patient and control samples.

Strengths

• Data generated by a consortium of seven pharmaceutical companies and a research institution, suggesting a collaborative scale.
• Focus on multiple facets of transcription across distinct brain regions and the human lifespan.
• Publicly available under a CC-BY-4.0 license, facilitating open research.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Last update date is unknown; freshness unverified.

Provenance

Source

Sage Bionetworks

Collection Method

Analysis of publicly available archival brain genomic data.

Time Range

Temporal coverage includes samples across the human lifespan, but specific dates are unknown.

Freshness

Last updated date is unknown.

Geography

Spatial coverage is not specified.